World's Best Scientists 2026 revealed!
Award Badge
Best Female Scientists
2025

D-Index & Metrics

Best Female Scientists

D-Index
140
Citations
73883
World Ranking
238
National Ranking
150

Medicine

D-Index
146
Citations
73539
World Ranking
1345
National Ranking
782

Research.com Recognitions

  • 2025 - Research.com Best Female Scientists Award
  • 2017 - Fellow of the American Association for the Advancement of Science (AAAS)

Overview

Kelly K. Hunt is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research focuses primarily on medicine with a significant emphasis on oncology and cancer-related fields. Hunt's contributions span multiple subfields, including oncology, cancer research, pulmonary and respiratory medicine, pathology and forensic medicine, and surgery.

The scientist's work extensively covers a range of topics in cancer studies and treatment. Key areas of research include breast cancer treatment studies, advanced breast cancer therapies, breast lesions and carcinomas, sarcoma diagnosis and treatment, breast implant and reconstruction, HER2/EGFR in cancer research, and cancer-related molecular pathways.

Kelly K. Hunt has a substantial record of publications, notably in the following venues:

  • Annals of Surgical Oncology
  • Cancer Research
  • Journal of Clinical Oncology
  • UNC Libraries
  • Cancers

Frequent collaborators in their research include Mediget Teshome, Khandan Keyomarsi, Christina L. Roland, Emily Z. Keung, and Keila E. Torres.

Significant recent papers authored or co-authored by Kelly K. Hunt include:

  • Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial (2020), published in UNC Libraries
  • Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100,000 women from 86 randomised trials (2023), published in The Lancet
  • Comparison of Cancer Prevalence in Patients With Neurofibromatosis Type 1 at an Academic Cancer Center vs in the General Population From 1985 to 2020 (2021), published in JAMA Network Open
  • Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial (2022), published in The Lancet Oncology
  • 2022 Practice Recommendation Updates From the World Consensus Conference on BIA-ALCL (2022), published in Aesthetic Surgery Journal

Kelly K. Hunt was recognized as a Fellow of the American Association for the Advancement of Science (AAAS) in 2017.

Best Publications

  • Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: A randomized clinical trial

    Armando E. Giuliano;Kelly K. Hunt;Karla V. Ballman;Peter D. Beitsch

  • Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial.

    Armando E. Giuliano;Linda McCall;Peter Beitsch;Pat W. Whitworth

  • Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

    Aman U. Buzdar;Nuhad K. Ibrahim;Deborah Francis;Daniel J. Booser

  • Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial

    Armando E. Giuliano;Karla V. Ballman;Linda McCall;Peter D. Beitsch

  • Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy

    Henry M. Kuerer;Lisa A. Newman;Terry L. Smith;Fred C. Ames

  • Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: The ACOSOG Z1071 (Alliance) Clinical Trial

    Judy C. Boughey;Vera J. Suman;Elizabeth A. Mittendorf;Gretchen M. Ahrendt

  • Whole-genome analysis informs breast cancer response to aromatase inhibition

    Matthew J. Ellis;Li Ding;Dong Shen;Jingqin Luo

  • Surgical Complications Associated With Sentinel Lymph Node Dissection (SLND) Plus Axillary Lymph Node Dissection Compared With SLND Alone in the American College of Surgeons Oncology Group Trial Z0011

    Anthony Lucci;Linda Mackie McCall;Peter D. Beitsch;Patrick W. Whitworth

  • Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection

    Abigail S. Caudle;Wei T. Yang;Savitri Krishnamurthy;Elizabeth A. Mittendorf

  • A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer

    Christos Hatzis;Lajos Pusztai;Vicente Valero;Daniel J. Booser

  • Surgical Complications Associated With Sentinel Lymph Node Biopsy: Results From a Prospective International Cooperative Group Trial

    Lee Gravatt Wilke;Linda M. McCall;Katherine E. Posther;Pat W. Whitworth

  • Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031

    Matthew J. Ellis;Vera J. Suman;Jeremy Hoog;Li Lin

  • Neoadjuvant Therapy with Paclitaxel followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same Regimen

    Aman U. Buzdar;Vicente Valero;Nuhad K. Ibrahim;Deborah Francis

  • Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.

    W. Fraser Symmans;Caimiao Wei;Rebekah Gould;Xian Yu

  • Primary treatment of cystosarcoma phyllodes of the breast.

    Arthur W. Chaney;Alan Pollack M.D.;Marsha D. Mcneese;Gunar K. Zagars

  • Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients with Sentinel Lymph Node Metastases: Long-Term Follow-Up from the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial

    Armando E. Giuliano;Karla Ballman;Linda McCall;Peter Beitsch

  • Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer.

    Y. Xing;M. Foy;D. D. Cox;H. M. Kuerer

  • Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks

    Marjorie C. Green;Aman U. Buzdar;Terry Smith;Nuhad K. Ibrahim

  • Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance).

    Judy C. Boughey;Karla V. Ballman;Huong T. Le-Petross;Linda M. McCall

  • Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant–Associated Anaplastic Large-Cell Lymphoma

    Mark W. Clemens;L. Jeffrey Medeiros;Charles E. Butler;Kelly K. Hunt

Frequent Co-Authors

Henry Mark Kuerer
Henry Mark Kuerer The University of Texas MD Anderson Cancer Center
Barry W. Feig
Barry W. Feig The University of Texas MD Anderson Cancer Center
Thomas A. Buchholz
Thomas A. Buchholz The University of Texas MD Anderson Cancer Center
Elizabeth A. Mittendorf
Elizabeth A. Mittendorf Brigham and Women's Hospital
Funda Meric-Bernstam
Funda Meric-Bernstam The University of Texas MD Anderson Cancer Center
Merrick I. Ross
Merrick I. Ross The University of Texas MD Anderson Cancer Center
Gildy Babiera
Gildy Babiera The University of Texas MD Anderson Cancer Center
S. Eva Singletary
S. Eva Singletary The University of Texas MD Anderson Cancer Center
Gabriel N. Hortobagyi
Gabriel N. Hortobagyi The University of Texas MD Anderson Cancer Center
Aysegul A. Sahin
Aysegul A. Sahin The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring related online degrees can open new doors for those interested in healthcare but not ready to commit to a full medical school program. For instance, becoming a medical coder is a fast-growing career, with medical billing and coding schools with financial aid making this field even more accessible.

Nursing is another rewarding pathway. Many universities now offer nursing programs without teas or other entrance exams, streamlining admission for aspiring nurses.

For those with leadership ambitions, an online health administration degree can lead to management roles in hospitals or clinics, with many programs designed to be completed quickly and flexibly.

Registered nurses looking to further specialize can explore adn to np bridge programs, allowing a direct path from an associate degree to becoming a nurse practitioner.

Each of these online options encourages progress in healthcare while accommodating busy schedules, different career goals, and varied educational backgrounds.

Best Scientists Citing Kelly K. Hunt

Trending Scientists

Recently Published Articles